Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 17/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 17/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 16/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 15/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 15/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 9/20 | 0.41 |
| ▸ | MEF2D | Q14814 | 2/20 | 0.38 |
| ▸ | CDK9 | P50750 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 9/20 | 0.37 |
| ▸ | HDAC7 | Q8WUI4 | 7/20 | 0.37 |
| ▸ | HDAC10 | Q969S8 | 7/20 | 0.37 |
| ▸ | HDAC11 | Q96DB2 | 7/20 | 0.37 |
| ▸ | HDAC9 | Q9UKV0 | 7/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL181678 | 1.00 | HDAC3 (0.41) | HDAC3HDAC6HDAC1HDAC4HDAC8 | |
| SCHEMBL181812 | 0.99 | HDAC4 (0.40) | HDAC3HDAC6HDAC1HDAC4HDAC8 | |
| SCHEMBL181811 | 0.99 | HDAC4 (0.40) | HDAC3HDAC6HDAC1HDAC4HDAC8 | |
| SCHEMBL181963 | 0.97 | HDAC4 (0.40) | HDAC3HDAC6HDAC1HDAC4HDAC8 | |
| SCHEMBL181962 | 0.97 | HDAC4 (0.40) | HDAC3HDAC6HDAC1HDAC4HDAC8 | |
| Trifluoroacetic Acid SCHEMBL9894994 | 0.93 | HDAC3 (0.38) | HDAC3HDAC6HDAC1HDAC4HDAC8 | |
| Trifluoroacetic Acid SCHEMBL9894997 | 0.93 | HDAC3 (0.38) | HDAC3HDAC6HDAC1HDAC4HDAC8 | |
| SCHEMBL10072100 | 0.92 | HDAC4 (0.38) | HDAC3HDAC6HDAC1HDAC4HDAC8 | |
| SCHEMBL7897997 | 0.87 | HDAC3 (0.56) | HDAC3HDAC6HDAC1HDAC4HDAC8 | |
| SCHEMBL9895603 | 0.87 | HDAC3 (0.56) | HDAC3HDAC6HDAC1HDAC4HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140155439-A1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2014-06-05 | — | — | US | claimed |
| US-20130303576-A1 | ENZYME INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2013-11-14 | — | — | US | claimed |
| US-20120149736-A1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2012-06-14 | — | — | US | claimed |
| EP-2401257-A1 | ENZYME INHIBITORS | Chroma Therapeutics Ltd. (GB) | 2012-01-04 | — | — | EP | claimed |
| WO-2010097586-A1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2010-09-02 | — | — | WO | claimed |
| US-9636409-B2 | Enzyme and receptor modulation using covalent conjugates of alpha,alpha-disubstituted glycine esters | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-05-02 | — | — | US | disclosed |
| US-20160151509-A1 | ENZYME AND RECEPTOR MODULATION | GLAXOSMITHKLINE IP DEV LTD (GB) | 2016-06-02 | — | — | US | disclosed |
| US-20140155439-A1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2014-06-05 | — | — | US | disclosed |
| US-20140088159-A1 | ENZYME AND RECEPTOR MODULATION | CHROMA THERAPEUTICS LTD. (GB) | 2014-03-27 | — | — | US | disclosed |
| US-20130303576-A1 | ENZYME INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2013-11-14 | — | — | US | disclosed |
| US-20120149736-A1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2012-06-14 | — | — | US | disclosed |
| US-20100317865-A1 | ENZYME AND RECEPTOR MODULATION | c/o Chroma Therapeutics Ltd. (GB) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303576-A1 | ENZYME INHIBITORS | HDAC1, HDAC4, HDAC3 | HDAC3 3/4885HDAC6 45/4885HDAC1 1/4885 |
| US-20140088159-A1 | ENZYME AND RECEPTOR MODULATION | CES1, GLRB, GLRA1 | HDAC3 2617/4885HDAC6 3490/4885HDAC1 2824/4885 |
| US-20140155439-A1 | ENZYME INHIBITORS | HDAC4, HDAC1, HDAC3 | HDAC3 3/4885HDAC6 77/4885HDAC1 2/4885 |
| US-20160151509-A1 | ENZYME AND RECEPTOR MODULATION | CES1, GLRB, GLRA1 | HDAC3 2617/4885HDAC6 3490/4885HDAC1 2824/4885 |
| US-20120149736-A1 | ENZYME INHIBITORS | HAT1, HDAC1, NAT1 | HDAC3 5/4885HDAC6 18/4885HDAC1 2/4885 |
| US-20100317865-A1 | ENZYME AND RECEPTOR MODULATION | CES1, GLRB, GLRA1 | HDAC3 2617/4885HDAC6 3490/4885HDAC1 2824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.